Metabolic disease
Conditions
Interventions
R1 group:0.1 mg/kg Remazolam Toluenesulfonate+0.5 mg/kg Propofol, add 0.5 mg/kg Propofol as needed
R2 group:0.15 mg/kg Remazolam Toluenesulfonate+0.5 mg/kg Propofol, add 0.5 mg/kg Propofol as needed
P group:Propofol 1.5mg/kg, IV for 1min, add propofol as needed, 0.5mg/kg/time
Sponsors
Xiangya III Hospital of Central South University
Eligibility
Sex/Gender
All
Age
65 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 65 <= age <= 75 years old, regardless of gender; 2. Patients receiving routine gastroscopy; 3. ASA scores from I to III; 4. 18 kg/m^2<BMI<30kg/m^2; 5. It is estimated that the operation time of gastroscope shall not exceed 30min; 6. Clearly understand, voluntarily participate in the study, and sign the informed consent form by himself.
Exclusion criteria
Exclusion criteria: Patients with any of the following cannot be included in this study: 1. Patients with psychosocial diseases and nervous system diseases; 2. Patients who take antipsychotic drugs such as tranquilizer and antianxiety, and who drink or abuse drugs; 3. Patients with language communication, vision or hearing impairment; 4. Complex endoscopic diagnosis and treatment technologies (such as cholangiopancreatography, endoscopic ultrasonography, endoscopic mucosal resection, endoscopic submucosal dissection, oral endoscopic myotomy, etc.) are required; 5. Patients to be intubated; The patient was judged as having difficulty in managing respiratory tract (the modified Markovian score was Grade IV); 6. Hypertension patients whose blood pressure was not controlled satisfactorily after antihypertensive drug treatment (sitting systolic blood pressure >= 160mmHg, and/or diastolic blood pressure >= 100mmHg in screening period); 7. SBP2, basic SpO2<92%); 10. Severe liver function damage; 11. Severe renal function damage; 12. Allergies to or contraindications to benzodiazepines, propofol, and their drug components; 13. Participated in clinical trials of Remazolam or other drugs as a subject in recent 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiopulmonary adverse events; | — |
Countries
China
Contacts
Public ContactZhiping Wang
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed